![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessEuropean LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
We sought to appraise the value of overall response and salvage chemotherapy, inclusive of allogeneic hematopoietic stem cell transplant (AHSCT), in primary refractory acute myeloid leukemia (prAML). For estab...
-
Article
Open AccessExtramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients
-
Article
Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
-
Article
Open AccessRisk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
In a recent International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) study, prior arterial events and hypertension were predictors of subsequent arterial thrombosis whereas ...
-
Article
Open AccessApplication of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
-
Article
Open AccessLiver function test abnormalities and their clinical relevance in primary myelofibrosis
-
Article
Open AccessPrognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
In 2012, the International Working Group for Myeloproliferative Neoplasms (MPN) Research and Treatment (IWG-MRT) reported an associations between mild bone marrow (BM) fibrosis (⩾grade 1) in polycythemia vera ...
-
Article
Open AccessPrognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients
Current prognostic models for myelodysplastic syndromes (MDS), including the Revised International Prognostic Scoring System (IPSS-R), do not account for host immunity. We retrospectively examined the prognost...
-
Article
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis
-
Article
Open AccessMPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
-
Article
Open AccessNumber and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
-
Article
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing
-
Article
Erratum: Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
-
Article
Open AccessSurvival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment
-
Article
Open AccessMolecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
-
Article
CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value
CD123 is the α-subunit of the interleukin-3 receptor; it represents a potential therapeutic target in systemic mastocytosis (SM) given its absent expression on normal/reactive mast cells (MCs) and aberrant exp...
-
Article
Open AccessImetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
-
Article
Open AccessPrognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
Mutations involving epigenetic regulators (TET2~60% and ASXL1~40%) and splicing components (SRSF2~50%) are frequent in chronic myelomonocytic leukemia (CMML). On a 27-gene targeted capture panel performed on 175 ...
-
Article
Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells
-
Article
Open AccessGenetic determinants of response and survival in momelotinib-treated patients with myelofibrosis